胰腺导管腺癌免疫治疗研究现状和展望

doi:10.11904/j.issn.1002-3070.2022.06.003

Abstract

Abstract: Pancreatic ductal adenocarcinoma(PDAC)is the most common type of pancreatic cancer,and the prognosis is extremely poor.Surgical resection is the only radical cure at present,but most patients have lost the chance of surgery when they seek medical adviee.As an emerging treatment,immunotherapy shows promising prospects in the treatment of various solid tumors and hematological malignancies.However,the low antigenicity and the immunosuppressive microenvironment of PDAC make its immunotherapy difficult.This article provides new ideas for the immunotherapy research of PDAC by reviewing the characteristics of the tumor microenvironment composition of PDAC and the current novel immunotherapy strategies.

Key words: Pancreatic ductal adenocarcinoma, Immune microenvironment, Immunotherapy, Immune evasion

CLC Number:

R735.9

GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma[J]. Journal of Practical Oncology, 2022, 36(6): 502-506.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.06.003

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I6/502

References

1 Wolfgang CL,Herman JM,Laheru DA,et al.Recent progress in pancreatic cancer[J].CA Cancer J Clin,2013,63(5):318-348.
2 Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer[J].N Engl J Med,2018,379(25):2395-2406.
3 Ohue Y,Nishikawa H.Regulatory T(Treg)cells in cancer:Can treg cells be a new therapeutic target?[J].Cancer Sci,2019,110(7):2080-2089.
4 Wang X,Lang M,Zhao T,et al.Cancer-FOXP3 directly activated CCL5 to recruit FOXP3⁺Treg cells in pancreatic ductal adenocarcinoma[J].Oncogene,2017,36(21):3048-3058.
5 Houchen CW,Li M.A subset of epithelial cells mimics regulatory T cells and contributes to immune evasion during development of pancreatic adenocarcinoma[J].BMC Med,2020,18(1):155.
6 Pylayeva-Gupta Y,Lee KE,Hajdu CH,et al.Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia[J].Cancer Cell,2012,21(6):836-847.
7 Gabrilovich DI.Myeloid-Derived suppressor cells[J].Cancer Immunol Res,2017,5(1):3-8.
8 Schmieder A,Michel J,Schnhaar K,et al.Differentiation and gene expression profile of tumor-associated macrophages[J].Semin Cancer Biol,2012,22(4):289-297.
9 Tanaka A,Sakaguchi S.Regulatory T cells in cancer immunotherapy[J].Cell Res,2017,27(1):109-118.
10 Steele CW,Karim SA,Leach JDG,et al.CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma[J].Cancer Cell,2016,29(6):832-845.
11 Liu J,Jiang W,Zhao K,et al.Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma[J].J Exp Med,2019,216(3):656-673.
12 Sharma MD,Baban B,Chandler P,et al.Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase[J].J Clin Invest,2007,117(9):2570-2582.
13 Sanford DE,Belt BA,Panni RZ,et al.Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer:a role for targeting the CCL2/CCR2 axis[J].Clin Cancer Res,2013,19(13):3404-3415.
14 Seo YD,Pillarisetty VG.T-cell programming in pancreatic adenocarcinoma:a review[J].Cancer Gene Ther,2017,24(3):106-113.
15 Morita T,Kodama Y,Shiokawa M,et al.CXCR4 in tumor epithelial cells mediates desmoplastic reaction in pancreatic ductal adenocarcinoma[J].Cancer Res,2020,80(19):4058-4070.
16 Johnson BA 3rd,Yarchoan M,Lee V,et al.Strategies for increasing pancreatic tumor immunogenicity[J].Clin Cancer Res,2017,23(7):1656-1669.
17 Mace TA,Shakya R,Pitarresi JR,et al.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer[J].Gut,2018,67(2):320-332.
18 Hu F,Guo F,Zhu Y,et al.IL-17 in pancreatic disease:pathogenesis and pharmacotherapy[J].Am J Cancer Res,2020,10(11):3551-3564.
19 Brower V.Checkpoint blockade immunotherapy for cancer comes of age[J].J Natl Cancer Inst,2015,107(3):69.
20 Iwai Y,Hamanishi J,Chamoto K,et al.Cancer immunotherapies targeting the PD-1 signaling pathway[J].J Biomed Sci,2017,24(1):26.
21 Royal RE,Levy C,Turner K,et al.Phase 2 trial of single agent Ipilimumab(anti-CTLA-4)for locally advanced or metastatic pancreatic adenocarcinoma[J].J Immunother,2010,33(8):828-833.
22 Padrón LJ,Maurer DM,O′Hara MH,et al.Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer:clinical and immunologic analyses from the randomized phase 2 PRINCE trial[J].Nat Med,2022,28(6):1167-1177.
23 Wang Y,Zheng K,Xiong H,et al.PARP inhibitor upregulates PD-L1 expression and provides a new combination therapy in pancreatic cancer[J].Front Immunol,2021,12:762989.
24 Aida K,Miyakawa R,Suzuki K,et al.Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer[J].Cancer Sci,2014,105(2):159-167.
25 Stanley ER,Chitu V.CSF-1 receptor signaling in myeloid cells[J].Cold Spring Harb Perspect Biol,2014,6(6):21857.
26 MacDonald KP,Palmer JS,Cronau S,et al.An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue and tumor-associated macrophages but does not inhibit inflammation[J].Blood,2010,116(19):3955-3963.
27 Zhu Y,Yang J,Xu D,et al.Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade[J].Gut,2019,68(9):1653-1666.
28 Klichinsky M,Ruella M,Shestova O,et al.Human chimeric antigen receptor macrophages for cancer immunotherapy[J].Nat Biotechnol,2020,38(8):947-953.
29 Bockorny B,Semenisty V,Macarulla T,et al.BL-8040,a CXCR4 antagonist,in combination with pembrolizumab and chemotherapy for pancreatic cancer:the COMBAT trial[J].Nat Med,2020,26(6):878-885.
30 Wang X,Li X,Wei X,et al.PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma(PDAC),and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC[J].Signal Transduct Target Ther,2020,5(1):38.
31 Manuel ER,Chen J,D′Apuzzo M,et al.Salmonella-Based therapy targeting undoleamine 2,3-Dioxygenase coupled with enzymatic depletion of tumor hyaluronan induces complete regression of aggressive pancreatic tumors[J].Cancer Immunol Res,2015,3(9):1096-1107.
32 Bahary N,Garrido-Laguna I.Phase 2 trial of the indoleamine 2,3-dioxygenase pathway(IDO)inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer:interim analysis[J].Journal Clinical Oncology,2016,34(15):3020.
33 Hall M,Liu H,Malafa M,et al.Expansion of tumor-infiltrating lymphocytes(TIL)from human pancreatic tumors[J].J Immunother Cancer,2016,4:61.
34 Poschke I,Faryna M,Bergmann F,et al.Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma[J].Oncoimmunology,2016,5(12):e1240859.

[1]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[2]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[3]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[4]	ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy [J]. Journal of Practical Oncology, 2022, 36(6): 513-519.
[5]	CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions [J]. Journal of Practical Oncology, 2022, 36(6): 520-525.
[6]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[7]	TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme [J]. Journal of Practical Oncology, 2022, 36(3): 278-282.
[8]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[9]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[10]	WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 79-83.
[11]	YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 542-546.
[12]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[13]	ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy [J]. Journal of Practical Oncology, 2021, 35(5): 441-446.
[14]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[15]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.

Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments